For the millions of women managing hormonal disruption, whether it surfaces as thyroid deficiency, cycle irregularity, or the stress-hormone patterns that compound both, this article looks at the peer-reviewed studies on how red light therapy impacts hormone health.
A randomized controlled trial found that women with autoimmune thyroid disease who received red light therapy needed less than half the thyroid medication of those who received a placebo. A six-year follow-up confirmed the difference held (Höfling et al., 2012; Höfling et al., 2018). A sustained medication reduction of that magnitude is a significant result. The evidence across other hormonal domains is earlier and less conclusive. But the direction is consistent enough to be worth understanding on its own terms.
Women exploring how red light therapy may support the hormonal shifts of perimenopause and beyond may also find red light therapy for menopause symptoms relevant.
Key Takeaways
- Red light therapy may help people suffering from hormonal imbalance by energizing hormone-producing cells, reducing the inflammation that disrupts hormonal signaling, and restoring blood flow to the thyroid, ovaries, and adrenal glands.
- The strongest evidence is in thyroid function: a randomized controlled trial with six-year follow-up found red light therapy significantly reduced medication requirements in women with autoimmune thyroid disease.
- Earlier-stage evidence, including animal studies, case series, and broad biochemical analysis, points to effects on cortisol regulation, ovarian activity, and reproductive outcomes, though clinical confirmation in women is still developing.
What Is Hormonal Imbalance in Women and Why Does It Matter?
Women's hormonal health runs on continuous signaling between the ovaries, thyroid, adrenal glands, and the brain regions that coordinate them. When one system falters, the effects cascade. Thyroid underperformance drags on energy and cycle regularity. Chronic stress elevates cortisol, which interferes with the brain signals telling the ovaries and thyroid to function normally. Inflammation compounds both.
Conventional treatment works by replacing what is missing or overriding what is misfiring: levothyroxine for thyroid underproduction, oral contraceptives for cycle regulation, hormone replacement therapy for what menopause depletes. Effective interventions, and fundamentally replacement strategies. The thyroid still underperforms; the medication fills the gap. For women who respond well, the system works. For those who remain symptomatic despite labs reading "normal," who cannot tolerate HRT due to risk factors, or who want to know whether the cellular dysfunction underneath the hormonal disruption can be addressed directly, the options narrow quickly. That clinical gap is where the research interest in red light therapy originates.
How Red Light Therapy May Improve Women's Hormone Health
Red light therapy delivers specific wavelengths of red and near-infrared light into tissue. The clinical term is photobiomodulation, or PBM. A 2021 clinical review confirmed that this process enhances energy production inside cells, improves cellular signaling, and reduces cellular damage caused by oxidative stress (Glass, 2021). The research connecting those cellular effects to women's hormonal outcomes spans several domains.
Thyroid Function
The most developed research for red light therapy and women's hormonal health comes from thyroid studies.
A 2010 pilot study of 15 patients with Hashimoto's thyroiditis (autoimmune thyroid disease) found that after low-level laser therapy, 47% of patients required no thyroid medication through the full nine-month follow-up (Höfling et al., 2010). That pilot led to a randomized, placebo-controlled trial of 43 patients. The results confirmed the signal: the laser group required an average daily thyroid medication dose of 38.59 µg compared to 106.88 µg in the placebo group, a statistically significant difference (Höfling et al., 2012). Six years later, a follow-up confirmed the laser group maintained significantly lower medication requirements and reported no safety concerns (Höfling et al., 2018).
A separate 2024 randomized controlled trial found that low-level laser therapy significantly improved oxidative stress markers and quality of life in patients with Hashimoto's thyroiditis compared to placebo treatment (Tunç et al., 2024). This study measured oxidative stress and quality of life rather than thyroid hormone levels directly, but it suggests an additional pathway: reducing the cellular damage that accumulates in inflamed thyroid tissue.
Cortisol Regulation
Chronically elevated cortisol disrupts women's hormonal balance through an indirect but well-established cascade. Sustained cortisol excess interferes with the brain signals that regulate ovarian and thyroid function, reducing their output over time.
A randomized controlled trial found that PBM significantly reduced cortisol levels in patients with chronic low back pain compared to placebo (Nardin et al., 2022). The cortisol-reducing effect was a predefined outcome and reached statistical significance, though the full data showed a more complex picture: cortisol responses varied depending on whether PBM was used alone or combined with other therapies. The study did not report whether participants were predominantly male or female.
Separately, a biochemical study in women with menstrual pain found that low-level light therapy was associated with lower cortisol levels compared to oral contraceptive treatment (Wang et al., 2023). That cortisol finding was one marker among 76 or more identified in a broad biochemical panel.
Ovarian and Reproductive Outcomes
An animal study found that PBM increased ovarian follicles and normalized key reproductive hormone levels in rats with induced PCOS (Alves et al., 2019). Whether the same effects occur in human ovarian tissue has not been tested.
A 2024 case series reported that three women with age-related infertility who received multiwavelength PBM went on to deliver healthy babies (Phypers et al., 2024). The authors framed this as hypothesis-generating, which is appropriate for a case series of this size. It cannot establish that the therapy caused the outcome, but it documents a clinical observation worth investigating further.
A clinical trial in postpartum women found that low-level laser therapy significantly elevated prolactin levels in those with insufficient lactation compared to untreated controls (Maged et al., 2019). This demonstrates that light can directly influence at least one hormone in a clinical setting, though prolactin regulation and broader reproductive hormone regulation involve different mechanisms.
Cellular Mechanisms
Several studies illuminate how red light therapy may support hormonal function at the cellular level.
A cell culture study found that PBM and estrogen independently protected the energy-producing structures inside cells under conditions of stress, and both modified smooth muscle cell behavior in comparable ways (Gavish et al., 2020). The study used pig arterial cells, and the authors' conclusion was specific to cardiovascular protection. The overlap in cellular mechanisms is interesting, though the study does not demonstrate that red light therapy replaces or replicates estrogen's effects in human endocrine tissue.
A 2025 animal study found that PBM reversed blood vessel dysfunction in estrogen-depleted rats, restoring vascular function to levels comparable to healthy controls (Silva et al., 2025). Improved circulation to hormone-producing glands could theoretically support their function. That connection has not been tested or measured directly.
A systematic review confirmed that PBM reduced oxidative stress markers and increased antioxidant enzyme production in muscle injury animal models (Dos Santos et al., 2017). That review examined skeletal muscle only. Whether the same antioxidant effects occur in endocrine tissue has not been studied.
Conclusion
Taken together, this body of research points to a consistent and meaningful pattern: red light therapy produces measurable improvements in hormone-related outcomes by working at the cellular and biochemical level. The thyroid evidence is particularly striking showing that light therapy significantly reduced the need for medication in women with autoimmune thyroid disease. The cortisol evidence, drawn from randomized controlled trials, shows that red light therapy reaches into the hormonal stress cascade that underlies so much of the disruption women experience. And the ovarian and reproductive findings, while earlier in their clinical development, point consistently in the same direction.
What I find most notable about this research is that the thyroid findings come with something rare in the complementary therapy space: long-term follow-up data. Most non-pharmacological interventions get a single trial and stop there. The six-year confirmation of medication reduction in the Höfling studies gives clinicians something concrete to evaluate. Red light therapy can be a valuable tool, and I have no safety concerns about patients exploring it alongside their existing treatment.— William Carter, MD
